Author of the publication

Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.

, , , , , and . Statistics in medicine, 22 (5): 763-80 (March 2003)5734<m:linebreak></m:linebreak>LR: 20071115; CI: Copyright 2003; GR: CA83932/CA/NCI NIH HHS/United States; JID: 8215016; 0 (Antineoplastic Agents); 0 (Immunosuppressive Agents); 0 (Piperazines); 0 (Pyrimidines); 152459-95-5 (imatinib); 21679-14-1 (fludarabine); 55-98-1 (Busulfan); 5536-17-4 (Vidarabine); ppublish;<m:linebreak></m:linebreak>Fase II.
DOI: 10.1002/sim.1399

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

An explanation of generalized profile likelihoods., and . Stat. Comput., 11 (4): 293-298 (2001)Bayesian designs to account for patient heterogeneity in phase II clinical trials., and . Current opinion in oncology, 20 (4): 407-11 (July 2008)Fase II; Disseny; Oncologia; Heterogeneïtat; Mètodes bayessians.On the structure of regular infinitely divisible point processes, and . Stochastic Processes and their Applications, 6 (1): 87--94 (November 1977)Some geometric methods for constructing decision criteria based on two-dimensional parameters. Journal of Statistical Planning and Inference, 138 (2): 516--527 (Feb 1, 2008)Determining the effective sample size of a parametric prior, , and . Biometrics, 64 (2): 595--602 (2008)Bayesian variable selection for a semi-competing risks model with three hazard functions., , , and . Comput. Stat. Data Anal., (2017)Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes., , , , , and . Statistics in medicine, 22 (5): 763-80 (March 2003)5734<m:linebreak></m:linebreak>LR: 20071115; CI: Copyright 2003; GR: CA83932/CA/NCI NIH HHS/United States; JID: 8215016; 0 (Antineoplastic Agents); 0 (Immunosuppressive Agents); 0 (Piperazines); 0 (Pyrimidines); 152459-95-5 (imatinib); 21679-14-1 (fludarabine); 55-98-1 (Busulfan); 5536-17-4 (Vidarabine); ppublish;<m:linebreak></m:linebreak>Fase II.